Literature DB >> 28372336

Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.

Inmaculada Lopez-Font1,2, Claudia P Boix1,2, Henrik Zetterberg3,4, Kaj Blennow3, Javier Sáez-Valero1,2.   

Abstract

We recently demonstrated that soluble forms of the amyloid-β protein precursor (sAβPP) assemble into multimeric complexes in cerebrospinal fluid (CSF), which contributes to the underestimation of specific sAβPP species when assessed by ELISA. To circumvent this issue, we analyzed by SDS-PAGE large fragments of sAβPP and their variants in the CSF from Alzheimer's disease (AD; n = 20) and control (n = 20) subjects, probing with specific antibodies against particular domains. Similar levels of sAβPPα and sAβPPβ protein were found in CSF samples from AD and controls, yet there appeared to be a shift in the balance of the soluble full-length AβPP (sAβPPf) species in AD samples, with a decrease in the proportion of the lower (∼100 kDa) band relative to the upper (∼120 kDa) band. Similar differences were observed in the contribution of the major KPI-immunoreactive AβPP species. CSF samples also displayed differences in the correlations of AβPP species with classical AD biomarkers, particularly with respect to the Aβ42 peptide. The differences reveal alterations that probably reflect pathophysiological changes in the brain.

Entities:  

Keywords:  Alzheimer’s disease; AβPP; KPI; biomarker; cerebrospinal fluid; sAβPPf; sAβPPα; sAβPPβ

Mesh:

Substances:

Year:  2017        PMID: 28372336     DOI: 10.3233/JAD-161275

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  4 in total

1.  Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments.

Authors:  Marianne K O Grant; Maureen Handoko; Malgorzata Rozga; Gunnar Brinkmalm; Erik Portelius; Kaj Blennow; Karen H Ashe; Kathleen R Zahs; Peng Liu
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

2.  Levels of ADAM10 are reduced in Alzheimer's disease CSF.

Authors:  Aitana Sogorb-Esteve; María-Salud García-Ayllón; Johan Gobom; Jordi Alom; Henrik Zetterberg; Kaj Blennow; Javier Sáez-Valero
Journal:  J Neuroinflammation       Date:  2018-07-25       Impact factor: 8.322

3.  α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease.

Authors:  Pablo Agüero; María José Sainz; María-Salud García-Ayllón; Javier Sáez-Valero; Raquel Téllez; Rosa Guerrero-López; Julián Pérez-Pérez; Adriano Jiménez-Escrig; Estrella Gómez-Tortosa
Journal:  Alzheimers Res Ther       Date:  2020-10-31       Impact factor: 6.982

4.  Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease.

Authors:  Claudia P Boix; Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Javier Sáez-Valero
Journal:  Alzheimers Res Ther       Date:  2020-08-12       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.